Q2 2024 Veracyte Inc Earnings Call Transcript
Key Points
- Veracyte Inc (VCYT) reported a strong second quarter with revenue of $114.4 million, marking a 27% increase compared to the prior-year period.
- Testing revenue grew by 31% year-over-year, driven by strong demand for Decipher and Afirma tests.
- The company achieved a GAAP net income of $5.7 million, marking its most profitable quarter to date.
- Veracyte Inc (VCYT) raised its total revenue guidance for 2024 to $432 million to $438 million, reflecting a significant improvement in the outlook for its testing business.
- The company reported an adjusted EBITDA margin of 21%, indicating strong fiscal management and profitability.
- Biopharmaceutical and other revenue decreased by 22% year-over-year, indicating challenges in this segment.
- Supply chain issues are expected to suppress the supply of the Prosigna nCounter test in the second half of the year and potentially beyond.
- The company anticipates a sequential decline in total revenue for the third quarter due to typical seasonality and prior-year period cash collections.
- Non-GAAP operating expenses increased by 14% year-over-year, driven by higher R&D and G&A expenses.
- The company faces challenges in securing commercial payer coverage for new test indications, which could impact future revenue growth.
Good day and thank you for standing by, and welcome to the Veracyte second-quarter 2024 financial results call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Shayla Gorman, Senior Director, Investor Relations. Please go ahead.
Good afternoon, everyone, and thank you for joining us today for a discussion of our second-quarter 2024 financial results. With me today are Marc Stapley, Veracyte's Chief Executive Officer; and Rebecca Chambers, our Chief Financial Officer. Veracyte issued a press release earlier this afternoon detailing our second-quarter 2024 financial results. This release, along with the business and financial presentation, is available in the Investor Relations section of our website at veracyte.com.
Before we begin, I'd like to remind you that various statements that we may make during this call will include forward-looking statements as defined under
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
